The U.S. Food and Drug Administration (FDA) has published its final guidance titled “Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs” (March 2026), providing a formalized scientific and regulatory framework for the evaluation of topical generic drug products.
This guidance consolidates the FDA’s current expectations for how applicants should characterize and compare the physicochemical and structural attributes (Q3) of topical formulations, particularly those classified as complex drug products due to their formulations and routes of delivery.
Key Summary
| Area | FDA position | Practical significance |
|---|---|---|
| Scope | Applies to liquid-based and semisolid topical dosage forms submitted in ANDAs | Broad relevance for creams, ointments, gels, lotions, emulsions, suspensions, and related products |
| Role of Q3 | Q3 characterization is used to describe physicochemical and structural attributes of the product | Shifts the focus from composition alone to the arrangement of matter within the formulation |
| Dosage form | Basic Q3 characterization can support confirmation that the test product and reference standard are the same dosage form | Important where dosage form names do not reliably describe structure |
| Bioequivalence | Comprehensive Q3 characterization can support assessment of whether structural differences may affect BE | Makes formulation structure part of the BE argument, not just a descriptive exercise |
| Comparative framework | Introduces Q3 sameness, Q3 similarity, and Q3 difference | Provides a clearer regulatory basis for interpreting comparative findings |
| Analytical burden | Recommends broader comparative characterization across relevant Q3 attributes | Raises expectations for topical generic development packages |
| Development strategy | Links Q3 data with IVRT, IVPT, manufacturing controls, and packaging effects | Requires more integrated formulation, process, and BE planning |
| FDA interaction | Encourages controlled correspondence and pre-ANDA meetings in appropriate cases | Supports earlier discussion of BE strategies for complex topical products |
Scope and Regulatory Context
The guidance applies to liquid-based and semisolid topical dosage forms intended for application to the skin or mucosal surfaces, including creams, ointments, lotions, emulsions, pastes, gels, suspensions, solutions, sprays, aerosols, foams, shampoos, and related systems.
The final guidance also reflects the FDA’s position that these products often fall within the category of complex drug products. That classification is tied not only to route of delivery, but also to formulation complexity and the possibility that structural differences may alter product performance. In practical terms, the FDA is drawing a firm distinction between a product’s ingredient list and the way that product is physically organized. For topical generics, that distinction can be decisive.
Conventional dosage form terminology is not sufficiently precise to establish structural equivalence. Products described as creams, ointments, lotions, or gels may differ materially in phase state, structural organization, and physicochemical behavior.
A cream, for example, may be a classic emulsion, while another product described as a cream may instead be an aqueous dispersion. An ointment may be oleaginous, emulsified, or based on polyethylene glycol. FDA therefore treats dosage form nomenclature as insufficient on its own and recommends direct Q3 characterization to support both dosage form identification and comparative assessment.
Definition and Role of Q3 Characterization
The FDA describes Q3 characterization as the evaluation of physicochemical and structural attributes that define how matter is arranged within a topical drug product. That characterization serves two distinct regulatory purposes.
The first is dosage form identification. Basic Q3 characterization can be used to show that the proposed generic product is the same dosage form as the reference standard. FDA identifies three elements that typically form this basic characterization:
- appearance and texture
- phase states
- structural organization of matter
This is a practical response to the limitations of conventional dosage form labels. When the dosage form name does not reliably define the product’s internal structure, comparative Q3 characterization provides a more objective basis for classification.
The second is support for bioequivalence. Comprehensive Q3 characterization provides a more detailed profile of attributes that may affect the local or systemic availability of the active ingredient.
FDA identifies several ways in which differences in Q3 attributes may become clinically relevant, including effects on solubility, stability, diffusion, partitioning, formulation metamorphosis on the skin, and thermodynamic activity of the active ingredient. In this framework, Q3 is not merely descriptive; it is part of the scientific basis for evaluating bioequivalence risk.
Structure of Q3 Characterization
The guidance distinguishes between basic and comprehensive Q3 characterization, and the distinction is more than procedural.
Basic Q3 characterization is intended primarily to establish the dosage form. It addresses how the product looks and feels, whether it is single- or multiphase, and how matter is structurally organized within the formulation.
Comprehensive Q3 characterization is intended to support a detailed comparative profile of product attributes that may be critical to performance. FDA lists ten categories of characterization that may be relevant, depending on the nature and complexity of the product:
- appearance and texture
- phase states
- structural organization of matter
- polymorphic form of the active ingredient, where suspended
- rheological behavior
- water activity and/or drying rate
- pH and buffering
- oleaginous components
- specific gravity
- metamorphosis-related changes
The guidance also states that these attributes should be characterized under conditions relevant to product behavior, including temperature, shear, time, and post-dispensing effects. Comparative Q3 characterization should be performed using at least three batches of the test product and, where available, three batches of the reference standard.
Several of these expectations are especially important for applicants. Rheological behavior is treated as a performance-relevant attribute rather than merely a supportive quality descriptor. FDA recommends complete flow characterization where feasible, including shear stress versus shear rate, viscosity versus shear rate, yield stress where plastic flow behavior exists, and linear viscoelastic response where relevant.
Microstructure is given a similar weight. FDA recommends representative high-resolution micrographs at multiple magnifications, supported by detailed sample-preparation information, to distinguish among single-phase products, multiphase systems, and products containing suspended matter. For emulsions, globule-size distribution and emulsion type should also be assessed.
The guidance also places notable emphasis on metamorphosis-related changes. FDA recognizes that topical products may change after dispensing, during evaporation, or over shelf life.
Packaging configuration may also affect the dispensed product. A formulation delivered from a tube may not behave identically to the same formulation dispensed from a pump. FDA states that when a Q3 attribute of the test product falls outside the range characterized for the reference standard, the difference may affect therapeutic performance.
Q3 Comparability Framework
One of the most useful features of the guidance is the introduction of a structured Q3 comparability framework. FDA defines three possible comparative outcomes: Q3 sameness, Q3 similarity, and Q3 difference. A simplified figure illustrating this framework appears in the guidance on page 9.
Q3 Sameness
FDA considers a test topical product to be Q3 the same as its reference standard where each relevant Q3 attribute falls within the characterized range, or acceptable variability, of the reference standard, and there is no difference in components or composition that may significantly affect local or systemic availability.
This is the most favorable outcome from a bioequivalence perspective. FDA states that Q3 sameness substantially mitigates the risk of bioequivalence failure modes associated with structural or physicochemical differences.
For topical solutions, this may support a waiver of in vivo evidence under appropriate conditions. For semisolids, it may support a more limited additional BE package when accompanied by acceptable comparative studies such as IVRT and IVPT, where relevant, particularly for emulsions.
Q3 Similarity
Q3 similarity applies where the relevant Q3 attributes remain within the characterized range, but the test product differs from the reference standard in components or composition in a way that may significantly affect availability.
In this situation, the comparative Q3 package addresses many potential risks, but not those arising from the specific formulation difference itself. The FDA, therefore, expects additional evidence directed to those remaining risks. The implication is that a product may still be scientifically defensible, but the justification must be narrower and more targeted.
Q3 Difference
Q3 difference applies where one or more relevant Q3 attributes of the test product fall outside the characterized range or acceptable variability of the reference standard.
The FDA does not prescribe a standard evidentiary path for such cases. That is an important regulatory signal. Once a product is Q3 different, the assessment becomes more product-specific, and the burden of justification becomes less predictable.
Link Between Q3 Attributes and Product Performance
The guidance explicitly links formulation structure to product performance. This is one of its most important scientific and regulatory features.
Rheology may affect spreadability, retention at the site of application, and release behavior. Microstructure may influence diffusion, partitioning, and permeation. Volatile components may drive evaporation-related changes that alter thermodynamic activity and delivery rate.
Phase distribution may affect both stability and dose uniformity. For petrolatum-based systems, the oleaginous composition may influence behavior in ways not captured by simply calling the product an ointment.
This structure-performance relationship is the foundation of the guidance. The FDA is making clear that for topical generics, equivalence cannot always be established by ingredient sameness alone. The way the formulation is organized, and how that organization changes during use, may be equally important to the regulatory assessment.
Implications for ANDA Applicants
For ANDA applicants, the guidance raises the level of formulation and analytical understanding expected in topical generic development.
Enhanced Analytical Expectations
Applicants should expect broader and more detailed comparative analytical packages, often across multiple batches and using methods capable of characterizing rheology, phase behavior, microstructure, and other performance-relevant Q3 attributes.
Integration With BE Strategy
The FDA does not position Q3 characterization as a stand-alone exercise. The guidance points applicants toward related tools, including in vitro release testing (IVRT) and in vitro permeation testing (IVPT), as part of the broader demonstration of equivalence. Q3 characterization therefore, needs to be integrated into the overall BE strategy from the outset.
Greater Importance of Manufacturing Control
The guidance also reinforces that Q3 attributes are influenced not only by formulation composition but by manufacturing conditions, aging, and packaging configuration. Process parameters, dispensing systems, and shelf-life changes may all affect the final comparative profile. This increases the importance of process understanding and development control in topical generic programs.
Early FDA Interaction
FDA encourages applicants developing topical products to use controlled correspondence for targeted questions and, for complex products, pre-ANDA meetings where appropriate. This is particularly relevant where no product-specific guidance exists or where the applicant intends to propose an alternative BE approach. The FDA also recommends that applicants perform at least basic Q3 characterization of the reference standard before initiating those interactions.
Conclusion
FDA’s final guidance on Q3 characterization provides a more defined regulatory framework for topical generic development. It clarifies how dosage form identification and bioequivalence assessment should be approached where formulation structure, phase behavior, rheology, and related physicochemical attributes are relevant to product performance.
Topical generics require more than compositional alignment with the reference product. Applicants are expected to characterize, compare, and justify the structural and physicochemical properties that may affect the product’s performance in use. By formalizing that expectation, the FDA has made the review standard for topical ANDAs more explicit and, at the same time, more scientifically coherent.
